Download PDF
Thromb Haemost 2008; 100(03): 515-516
DOI: 10.1160/TH07-12-0729
Letter to the Editor
Schattauer GmbH

The JAK2 V617F mutation is not a cause of central retinal vein occlusion

Cedric Hermans
1   Haemostasis and Thrombosis unit, Division of Haematology
,
Véronique Slachmuylder
2   Centre for Applied Molecular Technology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
,
Jean-Luc Gala
2   Centre for Applied Molecular Technology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
,
Catherine Lambert
1   Haemostasis and Thrombosis unit, Division of Haematology
,
Marie Detrait
1   Haemostasis and Thrombosis unit, Division of Haematology
› Author AffiliationsFinancial support: VS and JLG are supported by the followings grants: Communauté Française de Belgique Action de Recherche Concertée grant 04/09–317; Fondation Saint Luc and Centre du Cancer St Luc University Hospital Brussels, and grant Région Wallonne Nanotic/DEDIC-CAS 51/6250.
Further Information

Publication History

Received 09 December 2007

Accepted after major revision 27 June 2008

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
    CrossrefPubMedGoogle Scholar
  • 2 Hayreh SS, Zimmerman MB, Beri M. et al. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004; 111: 133-141.
    CrossrefPubMedGoogle Scholar
  • 3 Avashia JH, Fath DF. Bilateral central retinal vein occlusion in Waldenstrom's macroglobulinemia. J Am Optom Assoc 1989; 60: 657-658.
    PubMedGoogle Scholar
  • 4 Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 180-196.
    CrossrefPubMedGoogle Scholar
  • 5 Fegan CD. Central retinal vein occlusion and thrombophilia. Eye 2002; 16: 98-106.
    CrossrefPubMedGoogle Scholar
  • 6 Michiels JJ, Berneman ZN, Schroyens W. et al. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004; 15: 67-84.
    CrossrefPubMedGoogle Scholar
  • 7 Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290.
    CrossrefPubMedGoogle Scholar
  • 8 Michiels JJ, Koudstaal PJ, Mulder AH. et al. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1107-1110.
    CrossrefPubMedGoogle Scholar
  • 9 Landolfi R, Marchioli R, Kutti J. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124.
    CrossrefPubMedGoogle Scholar
  • 10 James C, Ugo V, Casadevall N. et al. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546-554.
    CrossrefPubMedGoogle Scholar
  • 11 James C, Ugo V, Le Couedic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
    CrossrefPubMedGoogle Scholar
  • 12 Primignani M, Barosi G, Bergamaschi G. et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
    CrossrefPubMedGoogle Scholar
  • 13 Michiels JJ, Commandeur S, Hoogenboom GJ. et al. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007; 86: 793-800.
    CrossrefPubMedGoogle Scholar
  • 14 Remacha AF, Estivill C, Sarda MP. et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285-286.
    CrossrefPubMedGoogle Scholar
  • 15 Janssen HL, Leebeek FW. JAK2 mutation:The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?. Hepatology 2006; 44: 1391-1393.
    CrossrefPubMedGoogle Scholar
  • 16 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 05: 708-714.
    CrossrefPubMedGoogle Scholar
  • 17 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Michiels JJ, De RH, Hebeda K, Lam KH. et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leuk Res 2007; 31: 1031-1038.
    CrossrefPubMedGoogle Scholar
  • 19 Arend O, Remky A, Jung F. et al. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 80-86.
    CrossrefPubMedGoogle Scholar
  • 20 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
    CrossrefPubMedGoogle Scholar
  • 21 Heron E, Marzac C, Feldman-Billard S. et al. Endogenous erythroid colony formation in patients with retinal vein occlusion. Ophthalmology 2007; 114: 2155-2161.
    CrossrefPubMedGoogle Scholar